Su Yanguang, Chen Juanli, Du Lingjun, Liu Xudong
Operating Room, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou, Zhejiang, China.
Ann Med. 2025 Dec;57(1):2530689. doi: 10.1080/07853890.2025.2530689. Epub 2025 Jul 11.
The fibrinogen-to-albumin ratio (FAR) has been extensively studied for its potential to predict the prognosis of patients with colorectal cancer (CRC). However, findings have been inconsistent. Therefore, this meta-analysis aims to examine the prognostic value of FAR in CRC.
A comprehensive search of PubMed, Web of Science, Cochrane Library, and Embase was conducted up to January 14, 2025. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the value of FAR for estimating overall survival (OS) and progression-free survival (PFS) in patients with CRC. Additionally, the relationship between FAR and CRC clinicopathological characteristics was explored using pooled odds ratios (ORs) with corresponding 95% CIs.
This meta-analysis included 10 studies comprising 4,704 patients. The findings indicated that elevated FAR was significantly associated with worse OS (HR = 1.59, 95% CI = 1.38-1.83, < 0.001) and PFS (HR = 1.65, 95% CI = 1.44-1.90, < 0.001) among patients with CRC. Subgroup analyses confirmed that high FAR consistently predicted unfavorable OS and PFS, regardless of study design, histology, treatment, FAR threshold, threshold determination method, or type of survival analysis (all < 0.05). Moreover, elevated FAR was significantly associated with age ≥60 years (OR = 1.56, 95% CI = 1.31-1.85, < 0.001), male sex (OR = 1.20, 95% CI = 1.01-1.43, = 0.042), and poor tumor differentiation (OR = 1.63, 95% CI = 1.26-2.10, < 0.001).
Elevated FAR is strongly associated with poor OS and PFS in patients with CRC, as well as with older age and poor tumor differentiation, suggesting its potential as a prognostic marker.
纤维蛋白原与白蛋白比值（FAR）预测结直肠癌（CRC）患者预后的潜力已得到广泛研究。然而，研究结果并不一致。因此，本荟萃分析旨在探讨FAR在CRC中的预后价值。
截至2025年1月14日，对PubMed、Web of Science、Cochrane图书馆和Embase进行了全面检索。计算风险比（HR）和95%置信区间（CI），以评估FAR对评估CRC患者总生存期（OS）和无进展生存期（PFS）的价值。此外，使用合并比值比（OR）及相应的95%CI探讨FAR与CRC临床病理特征之间的关系。
本荟萃分析纳入了10项研究，共4704例患者。研究结果表明，CRC患者中FAR升高与较差的OS（HR = 1.59，95%CI = 1.38 - 1.83，P < 0.001）和PFS（HR = 1.65，95%CI = 1.44 - 1.90，P < 0.001）显著相关。亚组分析证实，无论研究设计、组织学、治疗、FAR阈值、阈值确定方法或生存分析类型如何，高FAR始终预示着不良的OS和PFS（所有P < 0.05）。此外，FAR升高与年龄≥60岁（OR = 1.56，95%CI = 1.31 - 1.85，P < 0.001）、男性（OR = 1.20，95%CI = 1.01 - 1.43，P = 0.042）和肿瘤低分化（OR = 1.63，95%CI = 1.26 - 2.10，P < 0.001）显著相关。
FAR升高与CRC患者不良的OS和PFS密切相关，同时与年龄较大和肿瘤低分化有关，表明其作为预后标志物的潜力。
